No Data
No Data
No Data
No Data
No Data
4DMT to Participate in Upcoming Investor Conference
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
GlobeNewswireMay 7 20:00
4DMT Announces Presentations at ARVO 2024 Annual Meeting
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE,
GlobeNewswireMay 1 20:00
4D Molecular Therapeutics(FDMT.US) Officer Sells US$45,045 in Common Stock
$4D Molecular Therapeutics(FDMT.US)$ Officer Bizily Scott sold 1,750 shares of common stock on Apr 16, 2024 at an average price of $25.74 for a total value of $45,045.Source: Announcement What is stat
Futu NewsApr 19 09:31
4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital
4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital
Dow JonesApr 16 01:23
Royal Bank of Canada: Maintaining the 4D Molecular Therapeutics (FDMT.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $35.00 to $40.00.
Royal Bank of Canada: Maintaining the 4D Molecular Therapeutics (FDMT.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $35.00 to $40.00.
Zhitong FinanceApr 16 01:21
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40
RBC Capital analyst Luca Issi maintains 4D Molecular Therapeutics with a Outperform and raises the price target from $35 to $40.
Analyst UpgradesApr 16 01:13
No Data
No Data